Statistical and Trial Design Considerations in Central Nervous System Prophylaxis Studies

Keyphrases

• Accruals 33%
• Central Nervous System Involvement 33%
• Clinical Trials 33%
• CNS Metastases 33%
• Design Considerations 100%
• Early Termination 33%
• Ethics 33%
• Glioblastoma multiforme 33%
• High Risk 33%
• Initial Treatment 33%
• Non-Hodgkin Lymphoma 33%
• Operational Strategy 33%
• Patients with Cancer 33%
• Prophylactic Treatment 100%
• Risk Factors 33%
• Statistical Design 100%
• Statistical Issues 33%
• Treatment Outcome 33%
• Trial Design 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Central Nervous System Metastasis 100%

Medicine and Dentistry

• Central Nervous System Metastasis 33%